A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's Syndrome

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT03534323

Title field or adapter rule

{'original_value': "A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's Syndrome", 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-11-01T01:03:12.779730+00:00

Published At

2026-03-23T00:00:00+00:00

Record Updated At

2026-10-28

Results Posted At

2026-03-23

Source Retrieved At

2026-11-01T01:03:12.230707+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Chronic Lymphocytic Leukemia", "Richter Syndrome"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-28", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT03534323"

protocolSection.identificationModule.officialTitle

"A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter\u0027s Syndrome"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

{"date": "2026-03-23", "type": "ACTUAL"}

Study condition terms

• Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
• Richter Syndrome (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Phase 1 Level 1: 100 mg Venetoclax (daily) + 25 mg Duvelisib (BID)', 'Phase 1 Level 2: 200 mg Venetoclax (daily) + 25 mg Duvelisib (BID)', 'Phase 1 Level 3: 400 mg Venetoclax (daily) + 25 mg Duvelisib (BID)', 'Phase 2: 400 mg Venetoclax (daily) + 25 mg Duvelisib (BID)'], 'description': 'This drug is designed to stop cancer growth by blocking a protein called phosphatidylinositide 3-kinase (PI3K), which is important for the survival of CLL cells.', 'name': 'Duvelisib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Phase 1 Level 1: 100 mg Venetoclax (daily) + 25 mg Duvelisib (BID)', 'Phase 1 Level 2: 200 mg Venetoclax (daily) + 25 mg Duvelisib (BID)', 'Phase 1 Level 3: 400 mg Venetoclax (daily) + 25 mg Duvelisib (BID)', 'Phase 2: 400 mg Venetoclax (daily) + 25 mg Duvelisib (BID)'], 'description': 'Venetoclax targets a protein called BCL-2, which helps cancer cells survive.', 'name': 'Venetoclax', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Duvelisib (protocolSection.armsInterventionsModule.interventions[].name)
• Venetoclax (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.